.. APP receives FDA approval to market Gemcitabine HCI for Injection, USP in 2 g dosage APP Pharmaceuticals, Inc., a possessed subsidiary of Fresenius Kabi Pharmaceuticals Keeping wholly, Inc., announced today that it has received acceptance from the U.S. Food and Medication Administration to market Gemcitabine HCI for Injection, USP, in the two 2 g dosage strength. APP shall release this presentation of Gemcitabine immediately. In 2011 January, Teva Pharmaceuticals USA, Inc. Received authorization and APP Pharmaceuticals released Gemcitabine HCI for Injection in the 200 mg and 1g dosage forms within a commercialization, supply and manufacture agreement with Teva.Sankaran to get Rising Star AwardChildren's Memorial Hermann Medical center offers Halloween safety tips ‘The Restoration to Competency plan is an innovative way to provide important and effective treatment to detainees while safeguarding the interests of the public. It really is an honor to end up being recognized because of this success truly,’ said Mark W. Hale, President and Chief Executive Officer of Wexford Health. ‘We are always looking for partnership opportunities with our clients that may serve the public's interests in correctional health care.